Cargando…

S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS

Detalles Bibliográficos
Autores principales:	Garcia-Manero, G., Winer, E. S., DeAngelo, D. J., Tarantolo, S., Sallman, D. A., Dugan, J., Groepper, S., Giagounidis, A., Götze, K., Metzeler, K. H., Li, C.-C., Zhou, L., Martinez, E., Lane, M., von Roemeling, R., Bohme, M., Kubasch, A. S., Verma, A., Platzbecker, U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642083/ http://dx.doi.org/10.1097/01.HS9.0000843408.31385.3f

Ejemplares similares

P1298: THE IRAK-4 INHIBITOR EMAVUSERTIB (CA-4948) FOR THE TREATMENT OF PRIMARY CNS LYMPHOMA
por: Von Roemeling, C., et al.
Publicado: (2022)

P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
por: Joffe, E., et al.
Publicado: (2022)

IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies
por: Parrondo, Ricardo D., et al.
Publicado: (2023)

Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors
por: Guidetti, Francesca, et al.
Publicado: (2023)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
por: Von Roemeling, Christina A., et al.
Publicado: (2023)

IRAK1: oncotarget in MDS and AML
por: Beverly, Levi J., et al.
Publicado: (2014)

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
por: Kubasch, Anne Sophie, et al.
Publicado: (2018)

Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia
por: Garcia-Manero, Guillermo, et al.
Publicado: (2016)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
por: Jilg, Stefanie, et al.
Publicado: (2019)

PB1922: EFFECTIVENESS OF AZACITIDINE IN FRONTLINE HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A RETROSPECTIVE COHORT STUDY OF 382 PATIENTS
por: Rajakumaraswamy, N., et al.
Publicado: (2022)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts
por: Garcia-Manero, G, et al.
Publicado: (2017)

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype
por: Sallman, David A., et al.
Publicado: (2016)

Activation of distinct inflammatory pathways in subgroups of LR-MDS
por: Schneider, Marie, et al.
Publicado: (2023)

The role of innate immunity in MDS pathogenesis
por: Sallman, David A., et al.
Publicado: (2019)

The effect of azacitidine therapy on the M protein of MDS patients with concomitant MGUS
por: Oka, Satoko, et al.
Publicado: (2018)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
por: DeZern, A., et al.
Publicado: (2022)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Effect of 5-Azacitidine Treatment on Redox Status and Inflammatory Condition in MDS Patients
por: Montes, Paola, et al.
Publicado: (2022)

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
por: Platzbecker, U, et al.
Publicado: (2013)

Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape
por: Schwind, Sebastian, et al.
Publicado: (2021)

PP2A: The Achilles Heal in MDS with 5q Deletion
por: Sallman, David A., et al.
Publicado: (2014)

Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS
por: Buck, Michèle C., et al.
Publicado: (2023)

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
por: Cluzeau, Thomas, et al.
Publicado: (2012)

Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders
por: Polgarova, Kamila, et al.
Publicado: (2017)

Durable response of therapy-related MDS/AML with concomitant Waldenström’s macroglobulinemia treated with venetoclax and azacitidine
por: Hirano, Mitsuhito, et al.
Publicado: (2022)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

p38 MAPK in MDS
por: Gañán‐Gómez, Irene, et al.
Publicado: (2015)

Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?
por: Baer, Constance, et al.
Publicado: (2023)

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
por: Zeidan, Amer M., et al.
Publicado: (2018)

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease
por: Tobiasson, Magnus, et al.
Publicado: (2017)

Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML
por: Bennett, Joshua, et al.
Publicado: (2023)

Controversies on the Consequences of Iron Overload and Chelation in MDS
por: Vinchi, Francesca, et al.
Publicado: (2020)

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
por: Fenaux, Pierre, et al.
Publicado: (2018)

Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine
por: Miltiades, P, et al.
Publicado: (2014)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
por: Short, Nicholas J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q3cs6rt8aorahan3rqi023snkj